SEC Form 4 · accession 0000769993-16-001539
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adrian M Jones
Director
Period of report
Mar 9, 2016
Accepted (ET)
Mar 11, 2016 · 6:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1,F2 | $8.92 | Mar 9, 2016 | A | 66,176 | A | — | Mar 9, 2026 | Common Stock | 66,176 | 66,176 | I |
Explanation of responses
- F1The Reporting Person is a managing director of Goldman, Sachs & Co. ("Goldman Sachs"). Goldman Sachs is a wholly owned subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
- F2The options to purchase 66,176 shares of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. (the "Company") were granted to the Reporting Person in his capacity as a director of the Company pursuant to the T2 Biosystems, Inc. 2014 Incentive Award Plan. The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, which was March 9, 2016, subject to the Reporting Person continuing in service on the Company's board of directors through each such vesting date. The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.